1. Home
  2. ADEA vs WGS Comparison

ADEA vs WGS Comparison

Compare ADEA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adeia Inc.

ADEA

Adeia Inc.

N/A

Current Price

$13.01

Market Cap

2.6B

Sector

Technology

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

N/A

Current Price

$45.89

Market Cap

2.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ADEA
WGS
Founded
1990
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ADEA
WGS
Price
$13.01
$45.89
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$38.25
★ $82.00
AVG Volume (30 Days)
★ 1.5M
1.1M
Earning Date
11-02-2026
11-09-2026
Dividend Yield
★ 1.38%
N/A
EPS Growth
★ 73.68
62.37
EPS
★ 0.37
N/A
Revenue
★ $443,386,000.00
$427,539,000.00
Revenue This Year
N/A
$11.40
Revenue Next Year
$8.99
$19.61
P/E Ratio
$39.05
★ N/A
Revenue Growth
17.91
★ 39.97
52 Week Low
$11.93
$32.21
52 Week High
$34.34
$170.87

Technical Indicators

Market Signals
Indicator
ADEA
WGS
Relative Strength Index (RSI) 24.07 33.81
Support Level N/A $32.21
Resistance Level $26.48 $72.65
Average True Range (ATR) 0.94 5.39
MACD -0.19 -0.98
Stochastic Oscillator 0.70 4.82

Price Performance

Historical Comparison
ADEA
WGS

About ADEA Adeia Inc.

Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: